Alan Tan

My name is Alan Tan.

I'm a medical oncologist at the Vanderbilt Ingram Cancer Center.

It's my pleasure to host this discussion on bladder cancer or urothelial cancer with my good friends and GU experts in bladder cancer, Brad McGregor and Amanda Nizam.

Brad, you want to introduce yourself?

Yeah, so I actually used to be in Chicago, so I'm no stranger to blizzards and snow starts.

But now I'm here in Nashville where I'm actually craving some snow.

We're going to go Friday to Park City for a nice ski trip for my wife's birthday.

So that'll be nice.

Anyways, such exciting time.

I know we can talk for over an hour on urethelial cancer.

A lot has changed in the last few years.

But we're medical oncologists, and we usually see disease in a setting called MIBC, or muscle-invasive bladder cancer, or muscle-invasive urethral cancer.

Brad, why don't you start us off?

How has this discussion changed in the past few years when you're talking to a patient?

You refer to a patient by urology.

Patient has, say, T3 and zero disease, muscle invasive bladder cancer.

They got tube RPT assessment.

And what's the goal of the medical oncologist at this point?

Yeah, I totally agree, Brad.

Amanda, like when you talk to a patient, they ask what stage the cancer is.